Publication | Closed Access

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Hematological MalignancySurgical OncologyMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyRefractory Multiple Myeloma